The Omnipod® 5 App
Manage diabetes with freedom and flexibility
The Omnipod 5 App comes preloaded on an Insulet-provided Controller or can be used on a compatible smartphone*. It sends commands to the Pod, displays glucose and insulin information from the Pod, and can be used to give meal and correction boluses.
Automated insulin delivery (AID), at your fingertips
From setup to daily management, the Omnipod 5 App has you covered:
- Customized Settings: Personalize your insulin delivery by selecting basal profiles, target glucose levels, and bolus settings.
- Everyday Convenience: Deliver boluses with just a tap using the Omnipod 5 App on your Controller or compatible smartphone*.
- Simplified Site Changes: Follow in-app instructions to easily change a Pod or connect a sensor.
Consult the Omnipod 5 System User Guide for more information.
iPhone or Android—it’s your choice.
iPhone
Android
Controller
(Android)
Run the Omnipod 5 App on a compatible smartphone or use the Insulet-provided Controller.
*Smartphone compatibility factors include phone model, operating system, and sensor. Find the full list of compatible smartphones at Omnipod 5 Smartphone Compatibility.
Omnipod 5 System features
SmartAdjust™ Technology
To help protect against highs and lows1-3, our algorithm adjusts to your insulin needs every 5 minutes based on readings from your sensor. Watch SmartAdjust Technology 101 to learn more.
SmartBolus Calculator
The SmartBolus Calculator integrates your sensor glucose value and trend so you don't have to.
Activity Feature
When enabled, this feature reduces insulin delivery for times when glucose typically goes low, like during exercise
Custom Foods
Enter your own foods, snacks and meals with their carb count, your SmartBolus Calculator will have them ready to go every time you bolus.
Looking for more information?
1. Brown S. et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Average time with low blood glucose in adults/adolescents and children, standard therapy vs 3-month Omnipod 5: 2.9% vs. 1.3%; 2.2% vs. 1.8%. Study funded by Insulet.
2. Sherr JL, et al. Diabetes Care (2022). Study in 80 people with T1D aged 2 - 5.9 yrs involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 39.4% vs. 29.5%. Average time with low blood glucose in very young children, standard therapy vs 3-month Omnipod 5: 3.43% vs. 2.46%. Study funded by Insulet.
3. Pasquel FJ, et al. Presented at: ADA; June 21-24, 2024; Orlando, FL. Prospective pivotal trial in 305 participants with T2D aged 18-75 yrs. Study included a 14-day standard therapy (ST) phase followed by a 13-week Omnipod 5 hybrid closed-loop phase. Mean time >180 mg/dL as measured by CGM: ST = 54%, 3-mo Omnipod 5 = 34%, P<0.001. Mean time <70 mg/dL as measured by CGM: ST = 0.2%, 3-mo Omnipod 5 = 0.2%.